Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors, page-94

Would be nice and it was a good ride back then from 2c mind you it's very different drug stages - in 2013 it was Phase II clinical trial and the tipping point was Onyx taking SM6 for a combination. Now maybe a more interesting potential candidate and new tech but still very early stages and another year or 2 in the lab. But hey market can always surprise. They actually had more than twice the cash in bank that they have now but still moved on a $12M rights issue at a huge discount and killed it - I think everyone is hoping they learnt from that one.